| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2015-10-06 | BT-063 | systemic lupus erythematosus (SLE) | 2a | Biotest (Germany) | Autoimmune diseases |
| 2015-10-06 | IPH2201 (anti-NKG2A antibody) and ibrutinib | relapsed or refractory chronic lymphocytic leukemia | Innate Pharma (France) AstraZeneca (UK) | Cancer - Oncology | |
| 2015-10-06 | duvelisib | indolent non-Hodgkin lymphoma | 2 | Infinity Pharmaceuticals (USA - MA) | Cancer - Oncology |
| 2015-10-06 | OTI-15-01 | chronic diabetic foot ulcers | 3 | Osiris Therapeutics (USA - MD) | Metabolic diseases - Cardiovascular diseases |
| 2015-10-05 | Viaskin® Peanut | peanut allergy | 2b | DBV Technologies (France) | Allergic diseases - Immunological diseases |
| 2015-10-05 | PINTA 745 | chronic kidney disease | preclinical | Atara Biotherapeutics (USA - CA) | Kidney diseases - Renal diseases |
| 2015-10-05 | PINTA 745 | obesity, type II diabetes | preclinical | Atara Biotherapeutics (USA - CA) | Metabolic diseases |
| 2015-10-05 | PRX-106 (biosimilar version of etanercept) | NASH (non-alcoholic steatohepatitis) | preclinical | Protalix BioTherapeutics (Israel) | Liver diseases - Hepatic diseases |
| 2015-10-05 | ONS-1045 (biosimilar version of bevacizumab - Avastin®) | 1 | Oncobiologics (USA - NJ) | Cancer - Oncology | |
| 2015-10-05 | M923, a biosimilar version of Humira® (adalimumab) | chronic plaque psoriasis | 3a | Momenta Pharmaceuticals (USA - MA) Baxalta (USA - IL) | Autoimmune diseases – Dermatological diseases |
| 2015-10-05 | SCY-078 ((1,3)-ß-D-glucan synthesis inhibitor) | vulvovaginal candidiasis | 2 | Scynexis (USA - NJ) | Infectious diseases |
| 2015-10-02 | bamosiran (SYL040012) | ocular hypertension associated with glaucoma | 2b | Sylentis (Spain) | Ophtalmological diseases |
| 2015-10-01 | TAK-831 | schizophrenia, cerebellar ataxia | 1 | Takeda Pharmaceutical (Japan) | CNS diseases - Mental diseases |
| 2015-10-01 | T cell receptor (TCR) product candidate targeting HPV-16 E6 | Kite Pharma (USA - CA) | Cancer - Oncology | ||
| 2015-10-00 | FP-001 (leuprolide mesylate) | advanced prostate carcinoma | 3 | Foresee Pharmaceuticals (Taiwan, USA - DE) | Cancer - Oncology |
| 2015-09-30 | recAP - recombinant alkaline phosphatase | hypophosphatasia | preclinical | AM-Pharma (The Netherlands) | Rare diseases - Genetic diseases - Metabolic diseases |
| 2015-09-30 | BioChaperone Lispro | type 2 diabetes | 1b | Adocia (France) Eli Lilly (USA - IN) | Metabolic diseases |
| 2015-09-30 | GEN-1 IL-12 in combination with Avastin® and Doxil® | ovarian cancer | 1 | Celsion (USA - NJ) | Cancer - Oncology |
| 2015-09-30 | GEN-1 IL-12 in combination with neoadjuvant chemotherapy | ovarian cancer | 1 | Celsion (USA - NJ) | Cancer - Oncology |
| 2015-09-30 | CHEMOSAT® Delivery System | liver metastases from ocular melanoma | Delcath Systems (USA - NY) | Cancer - Oncology |
